Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
zalutumumab · 4 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| Zalutumumab | DRUG | Individual dose titration weekly i.v doses |
| Control | OTHER | Best Supportive Care |
Top 20 of 58 competitors
Zalutumumab is an investigational drug being studied for the treatment of head and neck neoplasms and head and neck cancer, including squamous cell carcinoma of the head and neck (SCCHN). It is developed by Genmab A/S and is currently in clinical development, with completed trials in these indications.
Zalutumumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). By binding to EGFR, it is designed to interfere with cancer cell growth and survival. This mechanism is being evaluated in clinical trials for head and neck cancer.
Zalutumumab is developed by Genmab A/S, a biopharmaceutical company listed on the Nasdaq Copenhagen stock exchange under the ticker GMAB. Genmab is responsible for the clinical development of this investigational drug for head and neck cancer.
Zalutumumab has completed Phase 1, Phase 2, and Phase 3 clinical trials. The most advanced trial, NCT00382031, was a Phase 3 study in patients with non-curable head and neck cancer. However, the drug is not approved and remains investigational, with no active trials currently listed.
Zalutumumab has been studied in four completed clinical trials: NCT00093041 (Phase 1/2), NCT00382031 (Phase 3), NCT00542308 (Phase 2), and NCT01054625 (Phase 1/2). These trials enrolled a total of 407 patients with head and neck cancer, including squamous cell carcinoma.
Zalutumumab is a specific monoclonal antibody targeting EGFR, similar in mechanism to other EGFR inhibitors, but it is a distinct investigational drug developed by Genmab. It is not known by any alternative names and is being studied specifically for head and neck cancer.